Centaur Trial (AMX0035): Longterm Survival Data

MOFF attended the NEALS webinar hosted by Dr. Sabrina Paganoni and Dr. Merit Cudkowicz on Wednesday, Oct 21, 2020. Click here to gain full access to the webinar once it becomes available.

Background Information

  • AMX0035 is a combination of two small molecule drugs: Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA).
  • The Centaur Trial (NCT03127514) looked at the functional impact of AMX0035 on the ALSFRS-R score of people living with ALS vs. a placebo. The total trial enrollment was 137.
  • The statistically significant Centaur Trial results are documented here. In short, the drug causes significant slowing of ALSFRS-R decline.
  • The open label extension of the Centaur Trial was utilized to observe the impact of AMX0035 on the long-term survival of people living with ALS.
  • The readout contained 35 months of data (beginning from initial trial enrollment period in 2017/2018).
  • The readout came from a comparison of trial participants who took AMX0035 vs. those who were administered a placebo.
Key Findings
  • The following results were disclosed by the principal investigator of the Centaur Trial, Dr. Sabrina Paganoni, during the webinar:
    • There was a 6.5 month longer median survival in the group originally randomized to AMX0035 than the placebo group. The median survival durations were 25 months and 18.5 months respectively.
    • Please read the Oct 16th Amylyx Pharmaceuticals press release of their long-term survival data findings here.
Both the placebo and non placebo groups had the option to take riluzole and/or endaravone. That being said, there was a sensitivity analysis done in both the function and survival studies. The sensitivity analysis concluded that AMX0035 had affects on top of the standards of care aka riluzole or endaravone.
Q & A
Q: Could this work for variants of ALS, such as primary lateral sclerosis (PLS)? A: Given the MOA of AMX0035, it is reasonable to think that it may be effective. However, no PLS patients were enrolled in the Centaur Trial.
Q: What is the route of administration? A: The formulation used in the Centaur Trial was a powder form of both drugs that you mix with water.
Q: Will it be affordable? A: Not determined at this time.
Q: Will AMX0035 be available through Expanded Access? A: Not determined at this time.
Q: Were there notable side effects? A: Mild nausea and diarrhea was common and expected in first 3 weeks of the trial.

Neil Clayton
Development Coordinator
MOFF is pleased to welcome Neil Clayton to the MOFF team as Development Coordinator and Strategic Thought Partner. Neil joins MOFF after working in law enforcement in San Luis Obispo County for over 20 years. During his law enforcement career, Neil volunteered with law enforcement-related non profits at both the local and state level. Neil recently retired from the SLO County District Attorney’s Office.

Neil supports MOFF’s mission and shares our organizational values having experienced the loss of a loved one to ALS in 2015. Driven by his experience with the challenges of caring for a loved one battling this disease locally, Neil is determined to help families living on the Central Coast find and maintain the medical care they need as well as do everything possible to support finding a cure.

In his spare time, Neil enjoys hiking, fishing and traveling with his wife Jennifer and their two children.

Gabriella Lyon
Social Media Coordinator
Gabriella is the Coordinator for Administrative Support at Associated Students, Inc. at Cal Poly San Luis Obispo. In her spare time, she serves as the Social Media Coordinator for MOFF. With a background in advocacy work and a personal understanding of the impact ALS has on families, Gabriella is committed to supporting and uplifting the ALS community. She holds a Bachelor of Arts degree in Communication and Sociology from the University of California, Davis.

Natalie Fernandez
Program Director, COO/CFO
Natalie is a Senior Consultant at Beghou Consulting. In her spare time she serves as Fractional COO/ CFO at MOFF. She is part of the Community Research Committee at the ALS Network and is a member of the Patient and Caregiver Advisory Committee at the ALS Association. Natalie holds an MBA degree in Pharmaceutical and Healthcare Business from the Philadelphia College of Pharmacy and an undergraduate degree from NYU. Natalie is motivated to find a cure for ALS to prevent individuals from experiencing what her mother, Martha, went through in her ALS journey. Natalie joined the ALS community when the saying was “ALS is not an incurable disease, it was just an underfunded one.” Today, it is now well funded. Let’s go! #findacureforALS

Andrea O'Brien
Board Member, Co-Founder, Secretary
Andrea O'Brien is a former HR professional who brings a wealth of experience in people and business to her role as Board Member, Co-Founder and Secretary at the Martha Olson-Fernandez Foundation. She holds a bachelor's degree from California Polytechnic State University and after building her professional career, she chose to dedicate her time to raising her son and daughter, embracing the opportunity to be present for their early years and family life. Her commitment to the Foundation is deeply personal, inspired by its namesake, her mother, Martha. Through her service, she honor's Martha's strength and resilience while advancing awareness, support and resources for individuals and families affected by ALS. She is proud to combine her professional experience and personal passion in support of the Foundation's mission.

John Ronca
Board Member
John joined the MOFF board of directors in April 2020. Bio coming soon.

Cheri Humphrey
Board Member
Cheri Humphrey joined the MOFF board of directors in August of 2019. Cheri grew up in Dixon, CA and moved to San Luis Obispo to attend Cal Poly. It was there that she met her husband Jim. They now reside in SLO and have a daughter, Victoria and a son, Riley. Cheri is instrumental in the operations of the iconic Madonna Inn, which she has been the Retail Manager of since 1989. Cheri and her family have been ALS advocates since the inception of MOFF. We are honored to have Cheri as part of the board to guide community outreach and continue raising awareness of ALS prevalence on the Central Coast.

Ian Parkinson
Board Member
We are very excited to welcome San Luis Obispo County Sheriff, Ian Parkinson, into his second two-year term as a member of the Martha Olson-Fernandez Foundation Board. Ian has served as Sheriff since 2011 and is well known in the community for this tireless efforts to improve the law enforcement processes of SLO County. Ian knew Martha Olson-Fernandez and has been a supporter of MOFF since 2012. We are very grateful for his commitment to help us carry out our mission to fight ALS through patient care and research. We look forward to utilizing his strategic insights and community outreach to further the MOFF mission.

Larry Fernandez
Director, CEO
Larry is a consultant in the vegetable seed industry. He has been an entrepreneur in the vegetable seed industry for 40 plus years. Larry is very proud of his daughter’s scholastic achievements, working careers and their growing families. He enjoys being a grandpa 3 times over, hunting and fishing when time permits. His goal in life is to honor his wife (Martha Olson-Fernandez) wishes of Finding a cure for ALS and assisting those living with ALS today so they never have to go through the processes she did while living with ALS.